AML17 Trial APL AIDA Induction ATRA Ida

AML17 Trial APL AIDA Induction ATRA Ida

<p> Canterbury DHB (Blood, Cancer and Palliative Care Service) Page 1 of 3</p><p>AML 17 - APL Height cm Consolidation Weight kg ATRA with Arsenic Trioxide BSA m2</p><p>Patient trial number: </p><p>Destination BMTU Limits Hypersensitivities/Allergies Agent Round Cycle 1 of 4 Date ATRA 10mg Neuts Idarubicin 1mg Plats DOSE MODIFIED: No Yes PRN antiemetics Reference: AML 17 trial protocol ± domperidone 20mg PO QID </p><p>Day Date Time Agent Dose Route Instructions Doctor Nurse Check Start Stop 1 Tretinoin (ATRA) 45mg/m2 mg PO Administered daily in 2 equally divided doses, for 2 weeks on followed by 2 weeks off, for a total of 7 cycles. Chart on QMR4 or outpatient script. 1 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.3mg/kg mg IV In 250ml 0.9% saline over 2 hours. 2 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.3mg/kg mg IV In 250ml 0.9% saline over 2 hours.</p><p> You must read the protocol before prescribing this chemotherapy. * Patients with a WCC > 10 X 109/l should receive gemtuzumab on day 1 and on day 4 if the WCC has not fallen below 10 X 109/l, otherwise delete. * Two doses of Rasburicase can be given on day 1 to prevent tumour lysis. * Monitor closely for signs of differentiation (ATRA) syndrome and tumorlysis syndrome. See Red book for details.</p><p>Patient Category: OSP Group: Consultant: Special Authority Y J A P O 1 3 Z 1 2 3 4 5 6 7 NZMC Reg. No: </p><p>Authorised by: PI RL Spearing Pharmacist: B Harden February 2011 D:\Docs\2018-04-06\076778f9f2ba8c74cdf8baab76c334ad.doc Review 2012 0 7 0 0 6 2 C T R A H C N O T A C D E M Y P A R E H T O M E H C I I Canterbury DHB (Blood, Cancer and Palliative Care Service) Page 2 of 3</p><p>AML 17 - APL AIDA treatment Height cm Consolidation Weight kg ATRA-IDA BSA m2</p><p>Day Date Time Agent Dose Route Instructions Doctor Nurse Check Start Stop 3 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.3mg/kg mg IV In 250ml 0.9% saline over 2 hours. 4 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.3mg/kg mg IV In 250ml 0.9% saline run over 2 hrs. 5 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.3mg/kg mg IV In 250ml 0.9% saline run over 2 hrs.</p><p>Authorised by: PI RL Spearing Pharmacist: B Harden February 2011 D:\Docs\2018-04-06\076778f9f2ba8c74cdf8baab76c334ad.doc Review 2012 0 7 0 0 6 2 C T R A H C N O T A C D E M Y P A R E H T O M E H C I I Canterbury DHB (Blood, Cancer and Palliative Care Service) Page 3 of 3</p><p>AML 17 - APL AIDA treatment Height cm Consolidation Weight kg ATRA-IDA BSA m2</p><p>WEEK Date Time Agent Dose Route Instructions Doctor Nurse Check Start Stop 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.25mg/kg mg IV In 250ml 0.9% saline over 2 hours. 2 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.25mg/kg mg IV In 250ml 0.9% saline over 2 hours. 3 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.25mg/kg mg IV In 250ml 0.9% saline over 2 hours. 3 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.25mg/kg mg IV In 250ml 0.9% saline over 2 hours. 4 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.25mg/kg mg IV In 250ml 0.9% saline over 2 hours. 4 0.9% saline 100 ml IV for flushing Arsenic trioxide 0.25mg/kg mg IV In 250ml 0.9% saline over 2 hours.</p><p>Authorised by: PI RL Spearing Pharmacist: B Harden February 2011 D:\Docs\2018-04-06\076778f9f2ba8c74cdf8baab76c334ad.doc Review 2012 0 7 0 0 6 2 C T R A H C N O T A C D E M Y P A R E H T O M E H C I I</p>

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    3 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us